TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

LEARNING OBJECTIVES

• Analyze how age, performance status and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with various presentations of AML.
• Evaluate the recent FDA approval of venetoclax in combination with a hypomethylating agent or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and discern how these regimens can be optimally integrated into nonresearch care algorithms.
• Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML.
• Develop an understanding of the mechanisms of action of, published data with and current clinical role of available IDH1/2 inhibitors for patients with AML and an IDH1 or 2 mutation.
• Review Phase III data supporting the recent FDA approval of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and consider how the availability of this novel strategy may affect clinical decision-making.
• Appraise ongoing clinical trials evaluating novel investigational approaches for AML, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Takeda Oncology; Contracted Research: Astellas, FUJIFILM Pharmaceuticals USA Inc.

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Member, Leukemia Program
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, NewLink Genetics; Consulting Agreements: AbbVie Inc, Arog Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc; Contracted Research: AbbVie Inc, Astellas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Leukemia & Lymphoma Society.

Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H Allen, MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Advisory Committee: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Kiadis Pharma, Novartis, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AbbVie Inc; Data and Safety Board/Committee: GlycoMimetics Inc, Takeda Oncology.

Eytan M Stein, MD
Assistant Attending Physician
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Ono Pharmaceutical Co Ltd, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, BioTheryX Inc, Bristol-Myers Squibb Company, Celgene Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Prelude Therapeutics, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc.

Andrew H Wei, MBBS, PhD
Adjunct Professor, Department of Haematology
Alfred Hospital and Monash University
Melbourne, Australia

Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, MacroGenics Inc, Novartis, Pfizer Inc, Servier; Consulting Agreement: Servier; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Novartis, Servier; Royalties: Former employee of the Walter and Eliza Hall Institute of Medical Research receiving a fraction of its royalty stream related to venetoclax; Speakers Bureau: AbbVie Inc, Genentech, a member of the Roche Group.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Helsinn Healthcare SA and Pfizer Inc.

Release date: January 2021
Expiration date: January 2022